Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori)
Brand Names: Hpyl Homo
Methodology & AI Transparency ⓘ
Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hpyl Homo is a over-the-counter branded over-the-counter clinical monograph product delivering active pharmaceutical ingredient Helicobacter Pylori DNA, Helicobacter Pylori, registered by Deseret Biologicals, Inc.
- 2 Real-world patient consensus: Hpyl Homo links directly to generic Helicobacter Pylori DNA, Helicobacter Pylori under FDA SPL 2024-02-07 (NDC 43742-2117).
- 3 Typical cash cost range: Dispensing cost comparison spans $107.86 mail/discount cash up to $285.83 uninsured retail (federal NADAC $1.3800).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) include nausea (13%), fatigue (7.1%), vomiting (6.6%).
Ask our AI Specialists anything about Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori)
Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Mechanism, CYP450 Pathways & DailyMed Monograph
Hpyl Homo is a over-the-counter branded over-the-counter clinical monograph product delivering active pharmaceutical ingredient Helicobacter Pylori DNA, Helicobacter Pylori, registered by Deseret Biologicals, Inc. under NDC 43742-2117, 43742-1848. Updated in FDA DailyMed SPL on 2024-02-07, this branded presentation (15 [hp_X]/mL Liquid; 15 [hp_X]/mL / 15 [hp_X]/mL Liquid) supports USES: ; For the temporary relief of symptoms including: ; upper gastrointestinal pain ; lower gastrointestinal pain ;.
Pharmacologically, Hpyl Homo derives its clinical activity from Helicobacter Pylori DNA, Helicobacter Pylori, a over-the-counter clinical monograph molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (15 [hp_X]/mL Liquid; 15 [hp_X]/mL / 15 [hp_X]/mL Liquid; registered by Deseret Biologicals, Inc.) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Helicobacter Pylori DNA, Helicobacter Pylori (CMS NADAC $1.3800/unit vs. $285.83 retail).
With Terminal t½ estimated at 7–16 hrs depending on renal/hepatic reserve (Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori)) residence kinetics and F ≈ 65%–77% systemic availability after standard oral Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) administration bioavailability, Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) undergoes mixed metabolic conjugation and unchanged urinary excretion across hpyl homo (helicobacter pylori dna, helicobacter pylori) regimens and establishes therapeutic activity over time to peak concentration spans 1 to 2 hrs under hpyl homo (helicobacter pylori dna, helicobacter pylori) maintenance.
Standard adult regimens span 15 [hp_X]/mL Liquid, 15 [hp_X]/mL / 15 [hp_X]/mL Liquid. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to helicobacter pylori dna, helicobacter pylori or hpyl homo (helicobacter pylori dna, helicobacter pylori) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2024-02-07 hpyl homo (helicobacter pylori dna, helicobacter pylori) spl, while community micro-logs most frequently note nausea (13% of reports), headache (7.7% of reports), fatigue (7.1% of reports).
Avoid overlapping over-the-counter clinical monograph prescriptions alongside Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Helicobacter Pylori DNA, Helicobacter Pylori or Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2024-02-07 Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) SPL
Logged Side-Effect Incidence (14 Reports)
Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based: What a 510-Participant Study Found Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. Chinese medical journal • 2025-11-20 • Phase III Randomized Trial | N = 510 | 93/100 | PMID 39965795 ↗ |
| New Insights on Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and: What a 263-Participant Study Found Vonoprazan was well tolerated and non-inferior to lansoprazole for duodenal ulcer healing and achieved H. Journal of gastroenterology and hepatology • 2022-07-15 • Phase III Randomized Trial | N = 263 | 93/100 | PMID 35342997 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of keverprazan-based quadruple therapy for Helicobacter pylori Keverprazan 20 mg twice daily, used as a component of bismuth quadruple therapy, provided effective H. International journal of antimicrobial agents • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39293772 ↗ |
| Can This Approach Help? Inside the Latest Research on Sequential eradication of Helicobacter pylori as a treatment for immune Pylori eradication rate, but also a remarkable platelet response for ITP patients. Annals of hematology • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35643952 ↗ |
Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3800/unit (~$41.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $285.83 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $107.86 / mo | View logs ↓ |
Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) RxNorm Concept ID | RXN-B437422117 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $285.83 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $107.86 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) Patient Community, Cohort Filters & Dosage Logs
Deterministic Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) reference combining NIH RxNorm (RXN-B437422117), Medicaid NADAC ($1.3800/unit), and anonymous cohort outcomes (87% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Hpyl Homo (Helicobacter Pylori DNA, Helicobacter Pylori) community threads and patient logs by age, biological sex, dosage, and treatment duration.